PriceTargets.com logo

Health Catalyst - HCAT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.69
  • Forecasted Upside: 123.37 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$11.95 As of 08/18/2022 03:58 PM ET
▲ +0.02 (0.17%)

This chart shows the closing price for HCAT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Health Catalyst Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCAT

Analyst Price Target is $26.69
▲ +123.37% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Health Catalyst in the last 3 months. The average price target is $26.69, with a high forecast of $48.00 and a low forecast of $16.00. The average price target represents a 123.37% upside from the last price of $11.95.

This chart shows the closing price for HCAT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 contributing investment analysts is to buy stock in Health Catalyst. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2021
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2021
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2021
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2021
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2022
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2022
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/18/2022
  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2022

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2022The Goldman Sachs GroupLower TargetBuy$29.00 ➝ $18.00Low
8/5/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$20.00 ➝ $16.00Low
8/5/2022Stifel NicolausDowngradeBuy ➝ Hold$27.00 ➝ $16.00Low
7/27/2022BTIG ResearchLower Target$35.00 ➝ $25.00Low
5/26/2022The Goldman Sachs GroupLower TargetBuy$42.00 ➝ $37.00Low
5/11/2022Canaccord Genuity GroupLower Target$35.00 ➝ $17.00High
5/11/2022Royal Bank of CanadaLower Target$35.00 ➝ $19.00High
5/11/2022CitigroupLower Target$45.00 ➝ $25.00High
5/11/2022Piper SandlerLower Target$38.00 ➝ $21.00High
4/13/2022GuggenheimInitiated CoverageBuy$39.00Medium
3/25/2022BTIG ResearchLower TargetBuy$60.00 ➝ $50.00Low
3/17/2022Jefferies Financial GroupUpgradeHold ➝ Buy$31.00 ➝ $28.00High
3/7/2022Piper SandlerLower TargetOverweight$66.00 ➝ $38.00Medium
3/4/2022Raymond JamesLower TargetStrong-Buy$70.00 ➝ $40.00High
3/2/2022Canaccord Genuity GroupLower Target$62.00 ➝ $35.00Low
3/2/2022Canaccord Genuity GroupLower TargetBuy$62.00 ➝ $35.00Medium
3/2/2022Royal Bank of CanadaLower TargetOutperform$66.00 ➝ $35.00High
3/2/2022SVB LeerinkLower TargetOutperform$64.00 ➝ $48.00High
2/11/2022The Goldman Sachs GroupInitiated CoverageBuy$48.00Low
12/20/2021CitigroupLower TargetBuy$68.00 ➝ $55.00Low
12/1/2021Jefferies Financial GroupInitiated CoverageHold$48.00High
10/14/2021BTIG ResearchInitiated CoverageBuy$60.00High
9/26/2021SVB LeerinkReiterated RatingBuyMedium
8/10/2021Raymond JamesBoost TargetStrong-Buy$66.00 ➝ $70.00High
8/10/2021Royal Bank of CanadaBoost TargetOutperform$60.00 ➝ $66.00High
8/9/2021CitigroupBoost TargetBuy$62.00 ➝ $68.00Low
8/6/2021SVB LeerinkBoost TargetOutperform$62.00 ➝ $64.00Medium
8/6/2021Piper SandlerBoost TargetOverweight$57.00 ➝ $66.00Low
6/30/2021SVB LeerinkBoost TargetOutperform$59.00 ➝ $62.00Medium
6/28/2021Raymond JamesReiterated RatingBuy$66.00Medium
5/7/2021The Goldman Sachs GroupBoost TargetBuy$54.00 ➝ $60.00High
5/7/2021Raymond JamesBoost TargetStrong-Buy$56.00 ➝ $63.00High
5/7/2021SVB LeerinkBoost TargetOutperform$53.00 ➝ $59.00High
5/7/2021Cantor FitzgeraldBoost TargetOverweight$52.00 ➝ $60.00High
5/7/2021Piper SandlerBoost TargetOutperform ➝ Overweight$54.00 ➝ $57.00High
4/29/2021JPMorgan Chase & Co.Initiated CoverageOverweightMedium
2/26/2021Piper SandlerBoost TargetOverweight$50.00 ➝ $54.00Low
2/26/2021SVB LeerinkBoost TargetOutperform$40.00 ➝ $53.00High
2/26/2021Raymond JamesBoost TargetIn-Line ➝ Strong-Buy$44.00 ➝ $56.00High
12/15/2020Smith Barney CitigroupBoost Target$40.00 ➝ $49.00Medium
12/8/2020Berenberg BankInitiated CoverageBuy$44.00High
11/11/2020Cantor FitzgeraldReiterated RatingOverweightHigh
11/11/2020Royal Bank of CanadaBoost TargetOutperform$34.00 ➝ $40.00Medium
11/11/2020Raymond JamesBoost TargetPositive ➝ Strong-Buy$40.00 ➝ $44.00High
8/18/2020GuggenheimBoost Target$33.00 ➝ $37.00Low
8/12/2020Truist FinancialBoost Target$36.00 ➝ $43.00High
8/12/2020Stifel NicolausBoost TargetBuy$36.00 ➝ $37.00High
7/14/2020CitigroupInitiated CoverageBuy$40.00Medium
7/10/2020SVB LeerinkBoost TargetOutperform$32.00 ➝ $40.00High
6/18/2020Stifel NicolausInitiated CoverageBuy$36.00High
6/4/2020Cantor FitzgeraldReiterated RatingBuy$44.00Medium
5/15/2020GuggenheimInitiated CoverageBuy$33.00Low
5/13/2020SunTrust BanksBoost TargetBuy$30.00 ➝ $36.00Medium
5/13/2020Royal Bank of CanadaBoost TargetOutperform$30.00 ➝ $34.00High
5/13/2020Raymond JamesLower TargetStrong-Buy$46.00 ➝ $40.00High
5/13/2020SVB LeerinkBoost TargetOutperform$31.00 ➝ $32.00High
4/22/2020SunTrust BanksLower TargetBuy$35.00 ➝ $30.00Low
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$30.00Low
4/20/2020Cantor FitzgeraldLower TargetPositive ➝ Overweight$47.00 ➝ $44.00Low
4/13/2020SVB LeerinkInitiated CoverageOutperform$31.00High
3/26/2020SunTrust BanksLower TargetBuy$46.00 ➝ $35.00Low
12/19/2019Raymond JamesInitiated CoverageStrong-Buy$46.00High
10/29/2019Cantor FitzgeraldInitiated CoverageOverweight$47.00High
8/19/2019SVB LeerinkInitiated CoverageOutperform$55.00Medium
8/19/2019The Goldman Sachs GroupInitiated CoverageBuy$49.00Medium
8/19/2019JPMorgan Chase & Co.Initiated CoverageOverweight$50.00High
8/19/2019Piper Jaffray CompaniesInitiated CoverageOverweight$47.00High
8/19/2019William BlairInitiated CoverageOutperformHigh
8/19/2019SunTrust BanksInitiated CoverageBuy$53.00High
8/19/2019Evercore ISIInitiated CoverageOutperform$50.00High
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/19/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/20/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/19/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/19/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
8/18/2022

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 7 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Health Catalyst logo
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
Read More

Today's Range

Now: $11.95
Low: $11.62
High: $11.98

50 Day Range

MA: $14.92
Low: $11.35
High: $18.27

52 Week Range

Now: $11.95
Low: $10.95
High: $57.19

Volume

13,378 shs

Average Volume

1,645,926 shs

Market Capitalization

$653.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Health Catalyst?

The following Wall Street research analysts have issued stock ratings on Health Catalyst in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Raymond James, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for HCAT.

What is the current price target for Health Catalyst?

13 Wall Street analysts have set twelve-month price targets for Health Catalyst in the last year. Their average twelve-month price target is $26.69, suggesting a possible upside of 123.4%. SVB Leerink LLC has the highest price target set, predicting HCAT will reach $48.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $16.00 for Health Catalyst in the next year.
View the latest price targets for HCAT.

What is the current consensus analyst rating for Health Catalyst?

Health Catalyst currently has 2 hold ratings, 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HCAT will outperform the market and that investors should add to their positions of Health Catalyst.
View the latest ratings for HCAT.

What other companies compete with Health Catalyst?

Other companies that are similar to Health Catalyst include Imago BioSciences, Kinnate Biopharma, Amarin, Cardiovascular Systems and ViewRay. Learn More about companies similar to Health Catalyst.

How do I contact Health Catalyst's investor relations team?

Health Catalyst's physical mailing address is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. The company's listed phone number is (801) 708-6800 and its investor relations email address is [email protected] The official website for Health Catalyst is www.healthcatalyst.com. Learn More about contacing Health Catalyst investor relations.